ImmunoPrecise Antibodies Ltd (NASDAQ: IPA)’s stock price has increased by 49.40 compared to its previous closing price of 0.49. However, the company has seen a 60.12% increase in its stock price over the last five trading sessions. businesswire.com reported 2025-01-22 that AUSTIN, Texas–(BUSINESS WIRE)—- $IPA #AI–ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes treatment. These AI-designed therapeutics aim to improve upon current GLP-1 therapies, which are widely used for managing type 2 diabetes and obesity. Created using the Company’s proprietary LENSai™ platform, an AI-driven system that an.
Is It Worth Investing in ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) Right Now?
Additionally, the 36-month beta value for IPA is 0.21. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IPA is 20.47M and currently, short sellers hold a 0.51% ratio of that float. The average trading volume of IPA on January 22, 2025 was 625.50K shares.
IPA’s Market Performance
IPA stock saw an increase of 60.12% in the past week, with a monthly gain of 70.10% and a quarterly increase of 36.39%. The volatility ratio for the week is 17.27%, and the volatility levels for the last 30 days are 13.42% for ImmunoPrecise Antibodies Ltd (IPA). The simple moving average for the last 20 days is 50.43% for IPA stock, with a simple moving average of -6.05% for the last 200 days.
Analysts’ Opinion of IPA
Many brokerage firms have already submitted their reports for IPA stocks, with H.C. Wainwright repeating the rating for IPA by listing it as a “Buy.” The predicted price for IPA in the upcoming period, according to H.C. Wainwright is $9 based on the research report published on December 02, 2022 of the previous year 2022.
The Benchmark Company, on the other hand, stated in their research note that they expect to see IPA reach a price target of $12. The rating they have provided for IPA stocks is “Buy” according to the report published on October 25th, 2021.
IPA Trading at 67.08% from the 50-Day Moving Average
After a stumble in the market that brought IPA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.67% of loss for the given period.
Volatility was left at 13.42%, however, over the last 30 days, the volatility rate increased by 17.27%, as shares surge +80.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +92.80% upper at present.
During the last 5 trading sessions, IPA rose by +64.85%, which changed the moving average for the period of 200-days by -47.70% in comparison to the 20-day moving average, which settled at $0.4907. In addition, ImmunoPrecise Antibodies Ltd saw 78.90% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for IPA
Current profitability levels for the company are sitting at:
- -0.55 for the present operating margin
- 0.5 for the gross margin
The net margin for ImmunoPrecise Antibodies Ltd stands at -1.14. The total capital return value is set at -0.28. Equity return is now at value -66.50, with -41.56 for asset returns.
Based on ImmunoPrecise Antibodies Ltd (IPA), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at -0.44. The debt to equity ratio resting at 0.5. The interest coverage ratio of the stock is -27.7.
Currently, EBITDA for the company is -22.95 million with net debt to EBITDA at -1.4. When we switch over and look at the enterprise to sales, we see a ratio of 1.86. The receivables turnover for the company is 4.78for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.01.
Conclusion
In conclusion, ImmunoPrecise Antibodies Ltd (IPA) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
